Log In
BCIQ
Print this Print this
 

revefenacin (TD-4208) (formerly GSK1160724)

  Manage Alerts
Collapse Summary General Information
Company Theravance Biopharma Inc.
DescriptionInhaled long-acting muscarinic antagonist (LAMA)
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation
PartnerMylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$265.0M

$15.0M

$220.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/02/2015

$265.0M

$15.0M

$220.0M

Get a free BioCentury trial today